

Accepted Manuscript

Three-year Continuation of Reversible Contraception

J.T. Diedrich, Ms. Q. Zhao, T. Madden, G.M. Secura, J.F. Peipert

PII: S0002-9378(15)00852-2

DOI: [10.1016/j.ajog.2015.08.001](https://doi.org/10.1016/j.ajog.2015.08.001)

Reference: YMOB 10565

To appear in: *American Journal of Obstetrics and Gynecology*

Received Date: 27 April 2015

Revised Date: 20 July 2015

Accepted Date: 2 August 2015

Please cite this article as: Diedrich JT, Zhao Q, Madden T, Secura GM, Peipert JF, Three-year Continuation of Reversible Contraception, *American Journal of Obstetrics and Gynecology* (2015), doi: 10.1016/j.ajog.2015.08.001.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



GENERAL GYNECOLOGY**Three-year Continuation of Reversible Contraception**

Diedrich JT, Ms. Zhao Q, Madden T, Secura GM, Peipert JF

From: Divisions of Family Planning and Clinical Research, Department of Obstetrics & Gynecology; Washington University School of Medicine in St Louis

ADDRESS CORRESPONDENCE TO:

Jeffrey F. Peipert, MD, PhD
Division of Clinical Research, Department of Obstetrics and Gynecology
Washington University in St. Louis School of Medicine
Campus Box 8219, 4533 Clayton Avenue
St. Louis, Missouri 63110
peipertj@wustl.edu
314-747-4016, office
314-747-6722, fax

DISCLOSURES: Drs. Diedrich and Secura and Ms. Zhao report no conflict of interest. Dr. Peipert receives research funding/support from Bayer, Teva, and Merck, and serves on advisory boards for Teva Pharmaceuticals and MicroCHIPs. Dr. Madden serves on an advisory board for Bayer Healthcare Pharmaceuticals and a data safety monitoring board for phase 4 safety studies of Bayer contraceptive products.

ACKNOWLEDGEMENTS: The Contraceptive CHOICE Project is funded an anonymous foundation. This publication also was supported by the Washington University Institute of Clinical and Translational Sciences grant UL1 TR000448 from the National Center for Advancing Translational Sciences and award number K23HD070979 from the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

SHORT TITLE: 3-Year Contraceptive Continuation

WORD COUNT: Abstract 245, Manuscript 2074

Download English Version:

<https://daneshyari.com/en/article/6144468>

Download Persian Version:

<https://daneshyari.com/article/6144468>

[Daneshyari.com](https://daneshyari.com)